Tweet
English version: Norwegian research breakthrough can solve CFS-mystery
Two oncologists in the city of Bergen in Norway have recently discovered a possible treatment for Chronic Fatigue Syndrome. The drug that they administered improved the condition of two out of three of the patients treated. Several patients were healed.
The results are sensational. Two out of three of the patients experienced major improvement, while some experienced a full recovery
The breakthrough, published today in the medical journal PLOS one, can provide answers to CFS-patients concerning what causes the mysterious disease and how it can be treated.
?We definitely see an effect. There is hope,? states professor and head of oncology at Haukeland University Hospital, Olav Mella to the TV 2 News.
Del p? facebook
TV 2 has exclusive access to the research paper that came out in the medical journal PLOS one. Mella and his colleague, attending MD ?ystein Fluge, have completed a double-blind study on 30 Norwegian CFS-patients.
The results are sensational. Two out of three of the patients experienced major improvement, while some experienced a full recovery.
....
Facts on Rituximab
Rituximab is a chimeric monoclonal antibody that attacks the B cells. The B cells are a form of leucocytes.
Rituximab is used in the treatment of many lymphomas, leukemias and some autoimmune disorders.
Rituximab destroys both normal and malignant B cells that have CD20 on their surfaces, and therefore used to treat diseases which are characterized by having too many B cells, overactive B cells or dysfunctional B cells.
Kilde: Wikipedia/ Md Phd ?ystein Fluge
Two oncologists in the city of Bergen in Norway have recently discovered a possible treatment for Chronic Fatigue Syndrome. The drug that they administered improved the condition of two out of three of the patients treated. Several patients were healed.
The results are sensational. Two out of three of the patients experienced major improvement, while some experienced a full recovery
The breakthrough, published today in the medical journal PLOS one, can provide answers to CFS-patients concerning what causes the mysterious disease and how it can be treated.
?We definitely see an effect. There is hope,? states professor and head of oncology at Haukeland University Hospital, Olav Mella to the TV 2 News.
Del p? facebook
TV 2 has exclusive access to the research paper that came out in the medical journal PLOS one. Mella and his colleague, attending MD ?ystein Fluge, have completed a double-blind study on 30 Norwegian CFS-patients.
The results are sensational. Two out of three of the patients experienced major improvement, while some experienced a full recovery.
....
Facts on Rituximab
Rituximab is a chimeric monoclonal antibody that attacks the B cells. The B cells are a form of leucocytes.
Rituximab is used in the treatment of many lymphomas, leukemias and some autoimmune disorders.
Rituximab destroys both normal and malignant B cells that have CD20 on their surfaces, and therefore used to treat diseases which are characterized by having too many B cells, overactive B cells or dysfunctional B cells.
Kilde: Wikipedia/ Md Phd ?ystein Fluge